The Center for Biosimilars® recaps the top news for the week of January 7, 2019.
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 7.
Number 5: Samsung Bioepis has announced that it will partner with biopharmaceutical company 3SBio to develop and commercialize multiple biosimilars in mainland China.
Number 4: The United Kingdom-based Patients Association recently released results of a survey and focus group that sought to understand patient needs in switching to biosimilars from reference products.
Number 3: At the J.P. Morgan Healthcare Conference, Coherus presented an overview of the company’s “branded approach” to selling its newly launched biosimilar pegfilgrastim, Udenyca.
Number 2: The Community Oncology Alliance recently formed a standing Biosimilars Committee aimed at educating providers.
Number 1: During the J.P. Morgan Healthcare Conference, Pfizer and Teva gave a look at their strategies for 2019 and beyond.
Finally, last week, our e-newsletter asked if new US policies to promote biosimilar insulins will help.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.